Compare Incyte Corporation (INCY) vs SoFi Technologies Inc (SOFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs SoFi Technologies Inc — how do they compare? Incyte Corporation trades at $115.71 (market cap $23.11B), while SoFi Technologies Inc trades at $17.15 (market cap $21.82B). The key difference: Incyte Corporation and SoFi Technologies Inc are close in size by market cap, and Incyte Corporation is trading nearer its 52-week high, SoFi Technologies Inc nearer its low. Which is the better fit depends on your goals.
| INCY | SOFI | |
|---|---|---|
Market Cap | $23.11B | $21.82B |
Sector | Health | Financials |
52-Week High | $118.52 | $32.21 |
52-Week Low | $67.38 | $15.15 |
Enterprise Value | $19.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
SOFI Technologies trades at $17.07, down 1.22% with a bearish technical signal. The company shows strong revenue growth, reaching $3.61B in 2025 with consistent earnings beats, though net income declined to $481M. Analyst consensus is mixed with a $22.43 price target, while recent news highlights upcoming Q2 earnings and takeover speculation.
SOFI presents growth potential with 30% revenue guidance and digital platform expansion, but faces risks from negative operating cash flow and competitive pressures. The stock's current valuation at 38.4 P/E requires continued execution to justify upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About SoFi Technologies Inc
SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Read more on SOFI →
